Trending NewsTrending NewsNASDAQ:PEPG PepGen (PEPG) Stock Price, News & Analysis $5.08 +0.37 (+7.86%) Closing price 10/2/2025 04:00 PM EasternExtended Trading$5.03 -0.05 (-0.98%) As of 04:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About PepGen Stock (NASDAQ:PEPG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PepGen alerts:Sign Up Key Stats Today's Range$4.77▼$5.1850-Day Range$1.01▼$5.8852-Week Range$0.88▼$9.94Volume2.22 million shsAverage Volume9.39 million shsMarket Capitalization$166.62 millionP/E RatioN/ADividend YieldN/APrice Target$8.40Consensus RatingModerate Buy Company Overview PepGen, Inc. (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration. The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome). These in vivo gene editing candidates are engineered to restore enzyme activity in affected tissues, potentially reducing the burden of repeated interventions. Beyond lysosomal storage disorders, PepGen is advancing earlier-stage research in inherited cardiovascular and metabolic conditions leveraging the same platform. Founded in 2020 by a cohort of genome engineering scientists, PepGen has assembled an interdisciplinary team with expertise in translational research, clinical development and regulatory strategy. The company’s research operations are based in San Diego, where it maintains research laboratories and manufacturing collaborations. PepGen also partners with academic institutions and clinical centers across the United States to support preclinical studies and future clinical trial sites. Under the leadership of Chief Executive Officer David Becker, who previously held senior roles at multiple biotechnology firms, PepGen is preparing its pipeline for regulatory interactions and human trials. The company has initiated strategic alliances to extend its capabilities in vector production and to explore commercialization pathways in North America and Europe.AI Generated. May Contain Errors. Read More PepGen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScorePEPG MarketRank™: PepGen scored higher than 75% of companies evaluated by MarketBeat, and ranked 269th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingPepGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPepGen has a consensus price target of $8.40, representing about 65.4% upside from its current price of $5.08.Amount of Analyst CoveragePepGen has only been the subject of 4 research reports in the past 90 days.Read more about PepGen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PepGen are expected to grow in the coming year, from ($2.73) to ($2.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PepGen is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PepGen is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPepGen has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about PepGen's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.02% of the float of PepGen has been sold short.Short Interest Ratio / Days to CoverPepGen has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PepGen has recently decreased by 0.88%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPepGen does not currently pay a dividend.Dividend GrowthPepGen does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.02% of the float of PepGen has been sold short.Short Interest Ratio / Days to CoverPepGen has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PepGen has recently decreased by 0.88%, indicating that investor sentiment is improving. News and Social Media3.7 / 5News Sentiment0.74 News SentimentPepGen has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for PepGen this week, compared to 6 articles on an average week.Search Interest3 people have searched for PEPG on MarketBeat in the last 30 days. MarketBeat Follows6 people have added PepGen to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, PepGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $640,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of PepGen is held by insiders.Percentage Held by Institutions58.01% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PepGen's insider trading history. Receive PEPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PepGen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PEPG Stock News HeadlinesPepGen (NASDAQ:PEPG) Major Shareholder Science Enterprises Plc Oxford Buys 200,000 SharesOctober 2 at 5:35 AM | insidertrades.comPepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle SocietyOctober 2 at 10:57 PM | finance.yahoo.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal. | Brownstone Research (Ad)PepGen Inc.: PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle SocietyOctober 2 at 5:57 PM | finanznachrichten.deRA Capital discloses increased PepGen stake at 29%October 1 at 2:42 PM | msn.comPepGen (PEPG) Price Target Increased by 21.95% to 8.50October 1 at 2:42 PM | msn.comPepGen Inc. (PEPG) Rating Upgraded With 135% Upside on FREEDOM DataSeptember 30 at 12:51 PM | insidermonkey.comBrokerages Set PepGen, Inc. (NASDAQ:PEPG) Price Target at $8.40September 28, 2025 | americanbankingnews.comSee More Headlines PEPG Stock Analysis - Frequently Asked Questions How have PEPG shares performed this year? PepGen's stock was trading at $3.79 at the start of the year. Since then, PEPG stock has increased by 34.0% and is now trading at $5.08. How were PepGen's earnings last quarter? PepGen, Inc. (NASDAQ:PEPG) released its earnings results on Thursday, August, 7th. The company reported ($0.70) earnings per share for the quarter, beating analysts' consensus estimates of ($0.85) by $0.15. When did PepGen IPO? PepGen (PEPG) raised $126 million in an IPO on Friday, May 6th 2022. The company issued 9,000,000 shares at $13.00-$15.00 per share. How do I buy shares of PepGen? Shares of PEPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PepGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that PepGen investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), Home Depot (HD) and Netflix (NFLX). Company Calendar Last Earnings8/07/2025Today10/02/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PEPG CIK1835597 Webwww.pepgen.com Phone781-797-0979FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for PepGen$8.40 High Price Target$12.00 Low Price Target$3.00 Potential Upside/Downside+65.4%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($2.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$89.98 million Net MarginsN/A Pretax MarginN/A Return on Equity-92.51% Return on Assets-70.39% Debt Debt-to-Equity RatioN/A Current Ratio4.74 Quick Ratio4.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.64 per share Price / Book1.40Miscellaneous Outstanding Shares32,800,000Free Float31,094,000Market Cap$166.62 million OptionableNot Optionable Beta1.92 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:PEPG) was last updated on 10/3/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredChina’s message to TrumpPorter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.